


Amendment to the Claims

Claims:

1. (Currently amended). A compound according to Formula I:



and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein:

R^1 is H;

R^2 is aryl, het, C_{3-8} cycloalkyl, C_{1-6} alkyl, $(CH_2)_z$ aryl or R^4 , wherein each of the cycloalkyl, aryl, het and R^4 groups is optionally substituted by at least one substituent independently selected from C_{1-6} alkyl, C_{1-6} alkoxy, OH, halo, CF_3 , OCF_3 , $OCHF_2$, $O(CH_2)_yCF_3$, CN, $CONH_2$, $CON(H)C_{1-6}$ alkyl, $CON(C_{1-6}alkyl)_2$, hydroxy- C_{1-6} alkyl, C_{1-4} alkoxy- C_{1-6} alkyl, C_{1-4} alkoxy- C_{1-4} alkoxy, SCF_3 , $C_{1-6}alkylSO_2$, $C_{1-4}alkyl-S-C_{1-4}alkyl$, $C_{1-4}alkyl-S-$, $C_{1-4}alkylNR^{10}R^{11}$ and $NR^{10}R^{11}$;

or R^1 and R^2 , together with the carbon atom to which they are bound, form a 5- or 6-membered carbocyclic ring or a 5- or 6-membered heterocyclic ring containing at least one N, O or S heteroatom;

where R^1 and R^2 are different, * represents a chiral centre;

R^3 is aryl, het or R^4 , each substituted by at least one substituent independently selected from C_{1-6} alkyl, C_{1-6} alkoxy, het, OH, halo, CF_3 , OCF_3 , $OCHF_2$, $O(CH_2)_yCF_3$, CN, $CONH_2$, $CON(H)C_{1-6}$ alkyl, $CON(C_{1-6}alkyl)_2$, hydroxy- C_{1-6} alkyl, C_{1-4} alkoxy- C_{1-6} alkyl, C_{1-4} alkoxy- C_{1-4} alkoxy, SCF_3 , $C_{1-6}alkylSO_2$, $C_{1-4}alkyl-S-C_{1-4}alkyl$, $C_{1-4}alkyl-S-$, $C_{1-4}alkylNR^{10}R^{11}$ and $NR^{10}R^{11}$;

R^4 is a phenyl group fused to a 5- or 6-membered carbocyclic group, or a phenyl group fused to a 5- or 6-membered heterocyclic group containing at least one N, O or S heteroatom;

R^5 is H or C_{1-6} alkyl;

R^{10} and R^{11} are the same or different and are independently H or C_{1-4} alkyl;

A is an unsubstituted methylene group;

x is an integer from 1 to 3;

y is 1 or 2;

z is an integer from 1 to 3;

aryl is phenyl, naphthyl, anthracyl or phenanthryl; and

het is an aromatic or non-aromatic 4-, 5- or 6-membered heterocycle which contains at least one N, O or S heteroatom, optionally fused to a 5- or 6-membered carbocyclic group or a second 4-, 5- or 6-membered heterocycle which contains at least one N, O or S heteroatom,

provided that when R¹ is H, R² is phenyl, A is CH₂ and x is 1, R³ is not 3-hydroxyphenyl or 3-(C₁₋₄alkoxy)phenyl, or a pharmaceutically acceptable salt thereof.

2. (Canceled).

3. (Currently amended). A compound or a pharmaceutically acceptable salt thereof according to Claim 1 ~~or Claim 2~~, wherein R² is aryl, het or C₃₋₈cycloalkyl, each optionally substituted by at least one substituent independently selected from C₁₋₆alkyl, C₁₋₆alkoxy, OH, halo, CF₃, OCF₃, OCHF₂, O(CH₂)_yCF₃, CN, CONH₂, CON(H)C₁₋₆alkyl, CON(C₁₋₆alkyl)₂, hydroxy-C₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₄alkoxy, SCF₃, C₁₋₆alkylSO₂ and C₁₋₄alkyl-S-C₁₋₄alkyl.


4. (Original). A compound or a pharmaceutically acceptable salt thereof according to Claim 3, wherein R² is aryl optionally substituted by at least one substituent independently selected from C₁₋₆alkyl, C₁₋₆alkoxy, OH, halo, CF₃, OCF₃, OCHF₂, O(CH₂)_yCF₃, CN, CONH₂, CON(H)C₁₋₆alkyl, CON(C₁₋₆alkyl)₂, hydroxy-C₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₄alkoxy, SCF₃, C₁₋₆alkylSO₂ and C₁₋₄alkyl-S-C₁₋₄alkyl.

5. (Original). A compound or a pharmaceutically acceptable salt thereof according to Claim 4, wherein R² is phenyl optionally substituted by at least one substituent independently selected from C₁₋₆alkyl, C₁₋₆alkoxy, OH, halo, CF₃, OCF₃, OCHF₂, O(CH₂)_yCF₃, CN, CONH₂, CON(H)C₁₋₆alkyl, CON(C₁₋₆alkyl)₂, hydroxy-C₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₄alkoxy, SCF₃, C₁₋₆alkylSO₂ and C₁₋₄alkyl-S-C₁₋₄alkyl.


6. (Currently amended). A compound or a pharmaceutically acceptable salt thereof according to ~~any preceding~~ claim 1, wherein R³ is aryl or R⁴, each substituted by at least one substituent independently selected from C₁₋₆alkyl, C₁₋₆alkoxy, OH, halo, CF₃, OCF₃, OCHF₂, O(CH₂)_yCF₃, CN, CONH₂, CON(H)C₁₋₆alkyl, CON(C₁₋₆alkyl)₂, hydroxy-C₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₄alkoxy, SCF₃, C₁₋₆alkylSO₂ and C₁₋₄alkyl-S-C₁₋₄alkyl.
7. (Original). A compound or a pharmaceutically acceptable salt thereof according to Claim 6, wherein R³ is phenyl substituted by at least one substituent independently selected from C₁₋₆alkyl, C₁₋₆alkoxy, OH, halo, CF₃, OCF₃, OCHF₂, O(CH₂)_yCF₃, CN, CONH₂, CON(H)C₁₋₆alkyl, CON(C₁₋₆alkyl)₂, hydroxy-C₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₆alkyl, C₁₋₄alkoxy-C₁₋₄alkoxy, SCF₃, C₁₋₆alkylSO₂ and C₁₋₄alkyl-S-C₁₋₄alkyl.
8. (Currently amended). A compound or a pharmaceutically acceptable salt thereof according to ~~any preceding~~ claim 1, wherein R⁵ is H or C₁₋₆alkyl.
9. (Currently amended). A compound or a pharmaceutically acceptable salt thereof according to ~~any preceding~~ claim 1, wherein x is 1.
10. (Original). A compound or a pharmaceutically acceptable salt thereof according to Claim 1 which is (+) or (-)-1-[2-(2-Ethoxyphenyl)-1-phenylethyl]piperazine.
11. (Original). A compound or a pharmaceutically acceptable salt thereof according to Claim 1 which is selected from the group consisting of:
- 1-{ 1-Phenyl-2-[2-(trifluoromethoxy)phenyl]ethyl }piperazine;
 - 1-{ 1-Phenyl-2-[2-chloro-6-fluorophenyl]ethyl }piperazine;
 - 1-{ 1-Phenyl-2-[2-chlorophenyl]ethyl }piperazine;
 - 1-{ 1-(3-Fluorophenyl)-2-[2-(trifluoromethoxy)phenyl]ethyl }piperazine;
 - 1-{ 2-[2-(Difluoromethoxy)phenyl]-1-phenylethyl }piperazine;
 - 1-{ 1-(4-Fluorophenyl)-2-[2-(trifluoromethoxy)phenyl]ethyl }piperazine;
 - 1-{ 1-(2-Fluorophenyl)-2-[2-(trifluoromethoxy)phenyl]ethyl }piperazine; and
 - 1-[2-(2-Methoxyphenyl)-1-phenylethyl]piperazine.

12. (Currently amended). A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof as claimed in ~~any one of~~ Claims 1 to 11 and a pharmaceutically acceptable adjuvant, diluent or carrier.
13. (Canceled).
14. (Canceled).
15. (Canceled).
16. (Canceled).
17. (Canceled).
18. (Currently amended). A method of treatment of a disorder in which the regulation of serotonin or noradrenaline is implicated which comprises administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof according to ~~any one of~~ Claims 1-11 to a patient in need of such treatment.
19. (Original). A method according to Claim 18, wherein the regulation of serotonin and noradrenaline is implicated.
20. (Currently amended). A method of treatment of urinary disorders, depression, pain, premature ejaculation, ADHD or fibromyalgia, which comprises administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof according to ~~any one of~~ Claims 1-11 to a patient in need of such treatment.
21. (Currently amended). A method according to Claim 20, wherein the urinary disorder is urinary incontinence, ~~such as GSI or USI~~.
22. (New). A method according to Claim 21, wherein the urinary disorder is genuine stress incontinence or stress urinary incontinence.

23. (Currently amended). A process for preparing a compound or a pharmaceutically acceptable salt thereof according to ~~any one of~~ Claims 1-11 comprising reacting a compound of Formula III



wherein R₂ and x are as defined in ~~any of~~ Claims 1 to 11 and PG is a protecting group;
with a compound of Formula IV



wherein R₃ and A are as defined in ~~any of~~ Claims 1 to 11, M is a metal selected from Zn and Mg and Hal is a halogen atom selected from chlorine, bromine and iodine;
and deprotecting the resultant compound.